Denali Therapeutics Inc.

DNLI

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001714899

None

No letter

6 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $1.1B
Standard universe	outside revenue above $1M and assets above $10M
Warnings	short runway, thin data, degenerate in... not computable: fortress balance sheet
Inputs computable	6 of 14
Graded from	filings received through Feb 26, 2026 259 days before the rescan; latest periodic filing 10-Q received Nov 3, 2026
Last close	$19.73 2026-11-11; market equity $3.2B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 26, 2026

Our purpose is to bring the power of biotherapeutics to the whole body, including the brain, by discovering, developing, and delivering medicines for people living with serious diseases. Historically, the blood-brain barrier has been a major challenge to the development of medicines for diseases of the central nervous system. While the blood-brain barrier protects the brain and is essential for our survival, it also prevents the delivery of medicines to the brain in sufficient quantities to have therapeutic effect.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 49.2						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(7.9%)	(6.6%)	49.2	801	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 20.3					
Twelve-month failure probability	0.04%	0.08%	19.5	247	2026-09-30
Altman Z double-prime	3.62	(0.35)	23.0	745	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	9.16x	2.95x	18.4	827	2025-12-31
Growth and financing, sleeve percentile 57.9					
Revenue growth, three-year compound	not computable	10.1%			
current value must be positive and the base must exceed $100,000					
Free cash flow growth, three-year compound	not computable	11.0%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	37.1%			
one or more required annual facts are missing					
Asset growth, three years	(7.8%)	2.2%	66.1	695	2025-12-31
Net share issuance, one year	9.2%	2.5%	49.8	628	2026-02-20

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 2.8 months
Thin data	6 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the $100,000 validity floor

What the price implies

at the 2026-11-11 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	27.0%	(1.9%)	67
Distance from 52-week high	(27.5%)	(27.8%)	51
EBIT to enterprise value	not computable	(1.6%)	
Free cash flow yield	(13.3%)	(1.0%)	29
Book value to price	0.29	0.27	53
Sales to price	0.00	0.29	0
Composite equity issuance, five years	28.1%	20.8%	55
Relative strength against the sector, log excess return	0.07	(0.19)	67

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Asset turnover improved	fail

Cash, filings, liquidity

Cash and equivalents	$102.9M
Operating cash flow, four quarters	-$444.2M
Months of runway	2.8
Days since last periodic filing	9 (10-Q received Nov 3, 2026)
Median daily dollar volume, 63 sessions	$28.9M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$512.5M	2025-12-31	2026-02-26	10-K	26-000021
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$412.6M	2025-12-31	2026-02-26	10-K	26-000021
3	assets	us-gaap:Assets	$1.1B	2025-12-31	2026-02-26	10-K	26-000021
4	assets	us-gaap:Assets	$1.4B	2024-12-31	2026-02-26	10-K	26-000021
5	current assets	us-gaap:AssetsCurrent	$900.7M	2025-12-31	2026-02-26	10-K	26-000021
6	current liabilities	us-gaap:LiabilitiesCurrent	$98.4M	2025-12-31	2026-02-26	10-K	26-000021
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$2.1B	2025-12-31	2026-02-26	10-K	26-000021
8	operating income	us-gaap:OperatingIncomeLoss	-$555.3M	2025-12-31	2026-02-26	10-K	26-000021
9	book equity	us-gaap:StockholdersEquity	$1.0B	2025-12-31	2026-02-26	10-K	26-000021
10	liabilities	us-gaap:Liabilities	$131.1M	2025-12-31	2026-02-26	10-K	26-000021
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$0	2025-12-31	2026-02-26	10-K	26-000021
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$0	2024-12-31	2026-02-26	10-K	26-000021
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$330.5M	2023-12-31	2026-02-26	10-K	26-000021
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$105.1M	2022-12-31	2025-02-27	10-K	25-000066
15	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$9.5M	2025-12-31	2026-02-26	10-K	26-000021
16	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$347.7M	2024-12-31	2026-02-26	10-K	26-000021
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$15.9M	2024-12-31	2026-02-26	10-K	26-000021
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$358.0M	2023-12-31	2026-02-26	10-K	26-000021
19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$12.9M	2023-12-31	2026-02-26	10-K	26-000021
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$244.7M	2022-12-31	2025-02-27	10-K	25-000066
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$17.8M	2022-12-31	2025-02-27	10-K	25-000066
22	assets	us-gaap:Assets	$1.2B	2023-12-31	2025-02-27	10-K	25-000066
23	assets	us-gaap:Assets	$1.5B	2022-12-31	2024-02-28	10-K	24-000086
24	shares outstanding	dei:EntityCommonStockSharesOutstanding	158,591,491	2026-02-20	2026-02-26	10-K	26-000021
25	shares outstanding	dei:EntityCommonStockSharesOutstanding	145,215,391	2025-02-21	2025-02-27	10-K	25-000066

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.